Chugai, Roche sales and marketing update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending RoActemra tocilizumab from Chugai as monotherapy for severe rheumatoid arthritis. The humanized mAb against IL-6 is marketed ...